Meeting
2024 ASCO Annual Meeting
Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).
Authors
Alexandra Ikeguchi
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Alexandra Ikeguchi , Takami Sato , Marcus O. Butler , Richard D. Carvajal , Joseph J Sacco , Alexander Noor Shoushtari , Jessica Cecile Hassel , Paul D. Nathan , Josep M. Piulats , Douglas Buckner Johnson , Jason J. Luke , Enrique Espinosa , Serge Leyvraz , Laura Collins , Ramakrishna Edukulla , Piruntha Thiyagarajah , Omid Hamid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02570308
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9529)
DOI
10.1200/JCO.2024.42.16_suppl.9529
Abstract #
9529
Poster Bd #
313
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma.
First Author: Paul D. Nathan
Poster
2023 ASCO Annual Meeting
Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.
First Author: Dan Feng
Poster
2023 ASCO Annual Meeting
Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.
First Author: Michael M Caplan
Poster
2022 ASCO Annual Meeting
Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis.
First Author: Ceren Durer